Keck School of Medicine

Doctors who treat patients with Alzheimer’s disease – even neurologists involved in clinical trials for Biogen, Inc. / Eisai Co., Ltd. ’s Aduhelm (aducanumab) – are unsure who actually should be trea

Below is Scrip’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Amgen, M

If flash gathered cash, optogenetics technology would be rolling in dough. The first paper showing that mammalian neurons could be readily engineered to respond to light was reported in 2005. In 2010,

The market for oncology companion diagnostics is poised for significant growth, according to Sagient Research Systems, an Informa company. Estimated at $2.55 billion for the top six indications (breas